Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma

References

• Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, et al.: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7, 347–353, 1993.
   Google Scholar
• Burris III HA, Moore MJ, Andersen JA, Green MR, Rothenberg ML, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15, 2403–2413, 1997.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364, 1817–1825, 2011.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, et al.: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369, 1691–1703, 2013.
   PubMed Web of Science ®Google Scholar
• Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M, et al.: Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol 23, 2645–2654, 2005.
   PubMed Web of Science ®Google Scholar
• Ito T, Urushima H, Sakaue M, Yukawa S, and Honda H.: Reduction of adverse effects by a mushroom product, active hexose correlated compound (AHCC) in patients with advanced cancer during chemotherapy: the significance of the levels of HHV-6 DNA in saliva as a surrogate biomarker during chemotherapy. Nutr Cancer 370, 377–382, 2014.
   Web of Science ®Google Scholar
• Hangai S, Iwase S, Kawaguchi T, Kogure Y, Miyaji T, et al.: Effect of active hexose-correlated compound in women receiving adjuvant chemotherapty for breast cancer: a retrospective study. J Altern Complement Med 19, 905–910, 2013.
   PubMed Web of Science ®Google Scholar
• Matsui Y, Uhara J, Satoi S, Kaibori M, Yamada H, et al.: Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol 37, 78–86, 2002.
   PubMed Web of Science ®Google Scholar
• Cowawintaweewat S, Manoromana S, Sriplung H, Khuhaprema T, Tongtawe P, et al.: Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment. Asian Pac J Allergy Immunol 24, 33–45, 2006.
   PubMed Web of Science ®Google Scholar
• IIshizuka R, Fujii H, Miura T, Fukuchi Y, and Tajima K.: Personalized cancer therapy for stage IV non-small cell lung cancer: combined use of active hexose correlated compound and genistein concentrated polysaccharide. Pers Med Univ 1, 39–44, 2012.
   Google Scholar
• Terakawa N, Matsui Y, Satoi S, Yanagimoto H, Takahashi K, et al.: Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind, placebo-controlled trial. Nutr Cancer 60, 643–651, 2008.
   PubMed Web of Science ®Google Scholar
• Takanari J, Hirayama Y, Homma K, Miura T, Nishioka H, et al.: Effects of active hexose correlated compound on the seasonal variations of immune competence in healthy subjects. J Evid-Based Complement Altern Med 20, 28–34, 2015.
   PubMedGoogle Scholar
• Furukawa H: Science of Mushroom, 1st ed. Kyoto, Japan: Kyoritsu Publications, 1992.
   Google Scholar
• Miura T, Kitadate K, Nishioka H, and Wakame K. Basic and clinical studies on active hexose correlated compound. In: Biotechnology in Functional Foods and Nutraceuticals, Bagchi D, Lau FC, Chosh DK (ed.). Boca Raton, FL: CRC Press Taylor and Francis Group, 2000, pp. 51–59.
   Google Scholar
• Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, et al.: CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13, 176–181, 2003.
   PubMed Web of Science ®Google Scholar
• Toiyama Y, Miki C, Inoue Y, Tanaka K, Mohri Y, et al.: Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. Exp Ther Med 2, 95–101, 2011.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45, 228–247, 2009.
   PubMed Web of Science ®Google Scholar
• Parida DK, Wakame K, and Nomura T: Integrating complementary and alternative medicine in form of active hexose correlated compound (AHCC) in the management of head & neck cancer patients. Int J Clin Med 2, 588–592, 2011.
   Google Scholar
• Thaiudom S, Piyaniran W, and Chutaputthi A: A study of the efficacy of active hexose correlated compound (AHCC) in the treatment of chronic hepatitis C patients at Phramongkutklao Hospital. Med News Thailand 325, 13–16, 2010.
   Google Scholar
• Kim JH and Im JA: Effect of active hexose correlated compound (AHCC) in alcoholic fatty liver patients. J Nutr Sci Vitaminol 60, 340–346, 2014.
   PubMed Web of Science ®Google Scholar
• Roman BE, Beli E, Duriancik DM, and Gardner EM: Short-term supplementation with active hexose correlated compound improves the antibody response to influenza B vaccine. Nutr Res 33, 12–17, 2013.
   PubMed Web of Science ®Google Scholar
• Fujii H, Nishioka H, Simon RR, Kaur R, Lynch B, et al.: Genotoxicity and subchronic toxicity evaluation of active hexose correlated compound (AHCC). Regul Toxicol Pharmacol 59, 237–250, 2011.
   PubMed Web of Science ®Google Scholar
• Mach CM, Fujii H, Wakame K, and Smith J: Evaluation of active hexose correlated compound hepatic metabolism and potential for drug interactions with chemotherapy agents. J Soc Integr Oncol 6, 105–109, 2008.
   PubMedGoogle Scholar
• Spierings ELH, Fujii H, Sub B, and Walshe T: A phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers. J Nutr Sci Vitaminol 53, 536–539, 2007.
   PubMed Web of Science ®Google Scholar
• Nakamoto D, Shigama K, Nishioka H, and Fujii H: Active hexose correlated compound (AHCC) alleviates gemcitabine-induced hematological toxicity in non-tumor-bearing mice. Int J Clin Med 3, 361–367, 2012.
   Google Scholar
• Shigama K, Nakaya A, Wakame K, Nishioka H, and Fujii H: Alleviating effect of active hexose correlated compound (AHCC) for anticancer drug-induced side effects in non-tumor-bearing mice. J Exp Therapeut Oncol 8, 43–51, 2009.
   PubMedGoogle Scholar
• Hirose A, Sato E, Fujii H, Sun B, Nishioka H, et al.: The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice. Toxicol Appl Pharmacol 222, 152–158, 2007.
   PubMed Web of Science ®Google Scholar
• Okada S, Ueno H, Okusaka T, Ikeda M, Furuse J, et al.: Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol 31, 7–12, 2001.
   PubMed Web of Science ®Google Scholar
• Lindley C, McCune JS, Thomason TE, Lauder D, Sauls A, et al.: Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Pract 7, 59–65, 1999.
   PubMedGoogle Scholar
• Bernhardson BM, Tishelman C, and Rutqvist LE: Self-reported taste and smell changes during cancer chemotherapy. Support Care Cancer 16, 275–283, 2008.
   PubMed Web of Science ®Google Scholar
• Jensen SB, Mouridsen HT, Bergmann OJ, Reibel J, Brünner N, et al.: Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106, 217–226, 2008.
   PubMed Web of Science ®Google Scholar
• Ravasco P, Monteiro-Grillo I, Vidal PM, and Camilo ME: Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 27, 659–668, 2005.
   PubMed Web of Science ®Google Scholar
• Brewin TB: Can a tumor cause the same appetite perversion or taste change as a pregnancy? Lancet 25, 907–908, 1980.
   Google Scholar
• DeWys WD: Changes in taste sensation and feeding behaviour in cancer patients: a review. J Hum Nutr 32, 447–453, 1978.
   PubMedGoogle Scholar
• Ripamonti C, Zecca E, Brunelli C, Fulfaro F, Villa S, et al.: A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer 82, 1938–1945.
   PubMed Web of Science ®Google Scholar
• Hong JH, Omur-Ozbek P, Stanek BT, Dietrich AM, Duncan SE, et al.: Taste and odor abnormalities in cancer patients. J Support Oncol 7, 58–65, 2009.
   PubMedGoogle Scholar
• McMillan DC, Crozier JEM, Canna K, Angerson WJ, and McArdle CS: Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorect Dis 22, 881–886, 2007.
   PubMed Web of Science ®Google Scholar
• Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DSJ, et al.: An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 104, 726–734, 2011.
   PubMed Web of Science ®Google Scholar